[Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].
Neurofibrillary tangles are the hallmark of Alzheimer's disease together with amyloid plaques. They are composed of hyperphosphorylated and aggregated Tau proteins. Consequently, experimental disease modifying approaches include kinase and aggregation inhibitors as well as substances which increase degradation of Tau proteins.
Schneider
A
A
Klinik für Psychiatrie und Psychotherapie, Gedächtnisambulanz, Universitätsmedizin Göttingen, Göttingen, Deutschland. aschnei8@gwdg.de
Falkai
P
P
Papassotiropoulos
A
A
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy; D018377:Neurotransmitter Agents / Q000627:therapeutic use*; D016875:tau Proteins / Q000378:metabolism*
D016229:Amyloid beta-Peptides; D018377:Neurotransmitter Agents; D016875:tau Proteins; D038362:Glycogen Synthase Kinase 3; D053829:Amyloid Precursor Protein Secretases